Cortechs.ai | Quantitative MRI and prostate cancer

Quantitative MRI and prostate cancer

Quantitative MRI for Prostate Cancer Detection and Monitoring AI Theater Presentation and RSNA 2021

(SAN DIEGO, Nov. 28, 2021)Cortechs.ai, creators of the first volumetric MRI AI application for clinical use, NeuroQuant, will be presenting new findings regarding the use of Quantitative MRI for Prostate Cancer Detection and Monitoring at this year’s Radiological Society of North America (RSNA) conference in Chicago. The presentation by Dr. Tyler Seibert MD, PhD will take place on Wednesday, December 1, 2021 at 2 p.m. in the AI Theater of the McCormick Place Convention Center. 

Tyler Seibert MD, PhD is a board-certified radiation oncologist, clinical translational researcher at UC San Diego, and one of Cortechs.ai’s Medical Advisory Board members. Seibert is experienced in complex data analysis, including development, validation, and translation of novel methods in both biomedical imaging and genetics. Innovations like OnQ Prostate are navigating cancer detection with data and precision that benefits physicians like Seibert with their analysis capabilities.

My top priority is to improve precision diagnosis and treatment of prostate cancer through quantitative imaging,” said Dr Seibert, “Together with our partners, Cortechs.ai has the ability to impart real innovation in the oncology MRI field.”

OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. The software leverages an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), powered by AI, to enable faster, more accurate identification of restricted diffusion. Cortechs.ai will be stationed at booth 4542 showcasing and demonstrating NeuroQuant, NeuroQuant MS, OnQ Prostate. In addition, OnQ Neuro, a recently FDA cleared device for automated brain tumor segmentation with RSI technology, will also be introduced. Schedule a meeting in advance with a clinical specialist or account manager by clicking here

To learn more about Cortech.ai at RSNA 2021, visit www.cortechs.ai/rsna. Fellow AI-powered partner Subtle Medical, a healthcare technology company with deep learning solutions will be close-by at booth 4538 and you can request a meeting here. Cortechs.ai and Subtle Medical are a powerful team that contributes to real, fast, and objective results with imaging software. Together, our technology drastically reduces scan time and analysis.

About Cortechs.ai

Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions and prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top